DOCSLIB.ORG

INVESTOR & ANALYST MEETING December 15, 2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
INVESTOR & ANALYST MEETING December 15, 2016 INVESTOR & ANALYST MEETING December 15, 2016 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, deterioration of or instability in the economy, the markets we serve and the financial markets, the impact of our restructuring activities on our ability to grow, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our ability to successfully identify, consummate and integrate appropriate acquisitions and successfully complete divestitures and other dispositions, our ability to integrate the recent acquisitions of Pall Corporation and Cepheid and achieve the anticipated benefits of those transactions, contingent liabilities relating to acquisitions and divestitures (including tax-related and other contingent liabilities relating to the distributions of each of Fortive Corporation and our communications business), our compliance with applicable laws and regulations (including regulations relating to medical devices and the healthcare industry) and changes in applicable laws and regulations, our ability to effectively address cost reductions and other changes in the healthcare industry, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, the impact of our debt obligations on our operations and liquidity, our relationships with and the performance of our channel partners, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, labor matters, international economic, political, legal, compliance and business factors (including the impact of the UK referendum to leave the EU), disruptions relating to man-made and natural disasters, security breaches or other disruptions of our information technology systems and pension plan costs. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2015 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2016. These forward-looking statements speak only as of the date of this presentation and the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise. With respect to any non-GAAP financial measures included in the following presentation, the accompanying information required by SEC Regulation G can be found in the “Investors” section of Danaher’s website, www.danaher.com, under the heading “Events & Presentations,” and event name “Danaher 2016 Investor & Analyst Meeting.” All references in this presentation to earnings, revenues and other company-specific financial metrics relate only to the continuing operations of Danaher’s business, unless otherwise noted. All references in this presentation to “growth” or other period-to-period changes refer to year-over-year comparisons unless otherwise indicated. We may also describe certain products and devices which have applications submitted and pending for certain regulatory approvals. Agenda 9:30 am Welcome Matt Gugino 9:35 am Opening Remarks Tom Joyce 10:05 am Life Sciences Dan Daniel Pall Rainer Blair Water Quality Lance Reisman Q&A Daniel, Blair, Reisman 11:00 am Break All 11:20 am Diagnostics Arnd Kaldowski Product Identification Joakim Weidemanis Dental Amir Aghdaei Q&A Kaldowski, Weidemanis, Aghdaei 12:15 pm Closing Remarks & Guidance Tom Joyce 12:25 pm Q&A Tom Joyce 12:40 pm Program End / Lunch OPENING REMARKS Tom Joyce, President & CEO Danaher Today Life Environmental & Diagnostics Dental Sciences Applied Solutions ~$5.3B revenue ~$5.0B revenue ~$2.8B revenue ~$3.7B revenue Water Quality Product ID All financial metrics shown reflect 2016 estimated (“2016E”) revenues from continuing operations. Building a multi-industry, science & technology company 2016 Highlights Team executing well in current macro environment Consistent core revenue growth across all 4 segments Estimated FCF of ~$2.5B expected to exceed Net Income for 25th consecutive year Expanding margins while reinvesting Core OMX up 90bps YTD Ex-Pall GM up 130bps y/y, G&A* down, R&D/S&M* up 90bps Announced and closed ~$5B in acquisitions, including Cepheid and Phenomenex ~10 deals across all 5 platforms Completed separation of Fortive in July * As a % of total revenues. All figures on this slide are for the nine months ended September 30, 2016 unless otherwise indicated. ~20% adjusted EPS growth y/y expected in 2016 What You’ll Hear Today Danaher Business System is our culture and our competitive advantage Outstanding portfolio with significant growth and margin opportunities Superior FCF generation and disciplined M&A help drive compounding long-term returns DBS is Our Culture DBS Principles and 8 Core Value Drivers Core Growth Shareholder OMX Cash Flow / WC Turns Leadership ROIC Quality (External PPM) Customer On-Time Delivery Growth Lean Associate Internal Fill Rate Retention “OMX” is Operating Margin Expansion; “WC” is Working Capital Expand capabilities, drive consistent execution, sustain results Leadership & Talent “The Best Team Wins” Infused DHR Retained Leaders Pall Leaders President General Managers Expectations of Danaher leaders CFO, Finance Technology Operations IT To lead through DBS Service Build leadership pipeline for their business, succession plans for critical roles Senior Leadership Team Talent development helps fuel performance Promoted Added Pall Talent External Export talent across Danaher Business Presidents Hires Ensure DBS leadership at acquisitions General Managers Legal HR Compliance Legal Sustaining the DBS culture across Danaher as we grow and evolve Danaher Business System is our culture and our competitive advantage Outstanding portfolio with significant growth and margin opportunities Superior FCF generation and disciplined M&A help drive compounding long-term returns Outstanding Portfolio – Overview Danaher Today ~55% Mid-teens >100% FREE CASH GROSS OPERATING By Business MARGIN FLOW TO NET MARGIN INCOME Dental 16% Diagnostics ~$17B 30% REVENUE EAS Business Characteristics 22% Life Market leading positions Outstanding brands Sciences 32% Resilient business models Large installed base By Mix By Geography Strong Secular Growth Drivers ROW Equipment 7% Increasing environmental, healthcare and food safety 35% HGM NA regulatory requirements and changes 29% 40% Consumables Improving standards of care in high growth markets (HGM) 65% EU Proliferation of digital trends 24% All financial metrics based on 2016E unless otherwise indicated. Strong growth, free cash flow and earnings profile Portfolio – Evolution Test & Other/ T&M T&M Measurement Niche Dental 15% Diagnostics Life Sciences17% Life Sciences 16% & Diagnostics Strengthening our & Diagnostics30% Environ- Environ- Environmentalmental competitive advantage mental 15% Life Tools with DBS Industrial IndustrialSciences 32%Dental Dental Technologies PID Technologies32% Motion Investing in the highest 10% Water 21% Quality impact growth 12% opportunities 2002 Today Revenue $4.6B Improving and ~$17B HGM %* ~8% sustaining our market- ~28% GM %* 39% leading positions ~55% Consumables %* < 15% ~65% Associates 29,000 *As a % of total revenues. 60,000+ Strategic priorities have helped drive portfolio evolution Portfolio – Key Initiatives Building Scale at the Recent Key Spin-off Platform Level Strategic Acquisitions of Fortive 2014 1999 Premium Implants Digital Dentistry 2015 2016 “Beachhead” Asset + Biopharmaceuticals Portfolio Optimization Adjacencies, Bolt-ons 2002 2016 Molecular Diagnostics Recent strategic initiatives helping to optimize Danaher’s portfolio for the long-term Portfolio – Business Model Well-established installed base drives aftermarket exposure, recurring revenues Equipment 35% Reduced revenue volatility Increased customer intimacy Consumables Higher margin opportunities enable 65% reinvestment Reinvestment fuels growth Consistently increased R&D, S&M Funded by higher GM, lower G&A Contributions of recent M&A ~75% ~95% ~75% All figures shown as a % of 2016E revenues. United by resilient business models with strong recurring revenue streams Portfolio – Growth Opportunity 1999 2005 2011 2016 Approximately ½ of our total revenue has been part of Danaher for 5 years or less DBS Driving Anticipated Core Revenue Growth Core Revenue Growth of Recent Acquisitions Water Quality MSD LSD MSD MSD Product
Load more

Recommended publications
  • DANAHER CORPORATION (Exact Name of Registrant As Specified in Its Charter)
    DANAHER CORP /DE/ FORM 10-K (Annual Report) Filed 3/10/2004 For Period Ending 12/31/2003 Address 2099 PENNSYLVANIA AVE N.W., 12TH FLOOR WASHINGTON, District of Columbia 20006 Telephone 202-828-0850 CIK 0000313616 Industry Scientific & Technical Instr. Sector Technology Fiscal Year 12/31 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2003 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-8089 DANAHER CORPORATION (Exact name of registrant as specified in its charter) Delaware 59-1995548 (State of incorporation) (I.R.S.Employer Identification number) 2099 Pennsylvania Ave. N.W., 12 th Floor Washington, D.C. 20006 -1813 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: 202-828-0850 Securities Registered Pursuant to Section 12(b) of the Act: Title of each class Name of Exchanges on which registered Common Stock $.01 par Value New York Stock Exchange, Inc. Pacific Stock Exchange, Inc. Securities registered pursuant to Section 12(g) of the Act: NONE (Title of Class) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • 2019 Annual Report
    1984 2019 2019 MARKED DANAHER’S 35TH ANNIVERSARY To honor this milestone, the front cover of this year's annual report features the original Danaher logo and bright blue color palette. We proudly celebrate our company's history as the prelude to a 35 future filled with opportunity. By living our core values of building the best team, continuously improving, “ listening to our customers every day and driving innovation, we ultimately deliver long-term shareholder value.” Thomas P. Joyce, Jr. Financial Operating Highlights (dollars in millions except per share data and number of associates) 2019 2018 Sales $ 17,911.1 $ 17,048.5 Operating Profit $ 3,269.4 $ 3,055.1 Net Earnings $ 2,432.3 $ 2,406.3 Net Earnings Per Share (diluted) $ 3.26 $ 3.39 Operating Cash Flow $ 3,657.4 $ 3,644.0 Investing Cash Flow $ (1,166.1) $ (2,873.9) Financing Cash Flow $ 16,589.9 $ (797.4) Capital Expenditures $ (635.5) $ (583.5) Capital Disposals $ 12.8 $ 6.3 Free Cash Flow (Operating Cash Flow less Capital Expenditures plus Capital Disposals) $ 3,034.7 $ 3,066.8 Number of Associates 60,000 58,000 Total Assets* $ 62,081.6 $ 47,832.5 Total Debt ** $ 21,729.1 $ 9,740.3 Stockholders’ Equity $ 30,281.9 $ 28,226.7 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 52,011.0 $ 37,967.0 * 2018 data includes both continuing and discontinued operations ** Long-Term Debt ($21,516.7 for 2019 and $9,688.5 for 2018) plus Notes Payable and Current Portion of Long-Term Debt ($212.4 for 2019 and $51.8 for 2018) All financial data set forth in this annual report relates solely to continuing operations unless otherwise indicated.
    [Show full text]
  • 2017 INVESTOR & ANALYST DAY December 14, 2017
    2017 INVESTOR & ANALYST DAY December 14, 2017 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, deterioration of or instability in the economy, the markets we serve and the financial markets, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify, consummate and integrate appropriate acquisitions and successfully complete divestitures and other dispositions, our ability to integrate the recent acquisitions of Pall Corporation and Cepheid and achieve the anticipated benefits of such transactions, contingent
    [Show full text]
  • Journal 2428
    Iris um Oifig Maoine Intleachtúla na hÉireann Journal of the Intellectual Property Office of Ireland Iml. 96 Cill Chainnigh 06 January 2021 Uimh. 2428 CLÁR INNSTE Cuid I Cuid II Paitinní Trádmharcanna Leath Leath Official Notice 1 Official Notice 1 Applications for Patents 3 Applications for Trade Marks 3 Patents Granted 4 Oppositions under Section 43 68 European Patents Granted 5 Application(s) Withdrawn 68 Applications Withdrawn, Deemed Withdrawn or Trade Marks Registered 69 Refused 151 Trade Marks Renewed 69 Request for Grant of Supplementary Protection Application(s) for Leave to Alter Registered Certificate 167 Trade Mark(s) 71 Supplementary Protection Certificate Withdrawn 168 Leave to Alter Registered Trade Mark(s) Supplementary Protection Certificate Rejected 168 Granted 71 Application for Extension of the Duration of a International Registrations under the Madrid Supplementary Protection Certificate 169 Protocol 72 Errata 170 International Trade Marks Protected 93 Cancellations effected for the following goods/services under the Madrid protocol 95 Dearachtaí Designs Information under the 2001 Act Designs Registered 171 The Journal of the Intellectual Property Office of Ireland is published fortnightly. Each issue is freely available to view or download from our website at www.ipoi.gov.ie © Rialtas na hÉireann, 2021 © Government of Ireland, 2021 1 (06/01/2021) Journal of the Intellectual Property Office of Ireland (No. 2428) Iris um Oifig Maoine Intleachtúla na hÉireann Journal of the Intellectual Property Office of Ireland Cuid I Paitinní agus Dearachtaí No. 2428 Wednesday, 6 January, 2021 NOTE: The office does not guarantee the accuracy of its publications nor undertake any responsibility for errors or omissions or their consequences.
    [Show full text]
  • 2018 Annual Report
    2018 Annual Report Danaher 2018 Annual Report Financial Operating Highlights (dollars in millions except per share data and number of associates) 2018 2017 Sales $ 19,893.0 $ 18,329.7 Operating Profit $ 3,403.8 $ 2,990.4 Net Earnings $ 2,650.9 $ 2,469.8 Net Earnings Per Share (diluted) $ 3.74 $ 3.50 Operating Cash Flow $ 4,022.0 $ 3,477.8 Investing Cash Flow $ (2,949.4) $ (843.4) Financing Cash Flow $ (797.4) $ (3,098.5) Capital Expenditures $ (655.7) $ (619.6) Capital Disposals $ 6.3 $ 32.6 Free Cash Flow (Operating Cash Flow less Capital Expenditures plus Capital Disposals) $ 3,372.6 $ 2,890.8 Number of Associates 71,000 67,000 Total Assets $ 47,832.5 $ 46,648.6 Total Debt * $ 9,740.3 $ 10,522.1 Stockholders’ Equity $ 28,226.7 $ 26,367.8 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 37,967.0 $ 36,889.9 * Long-Term Debt ($9,688.5 for 2018 and $10,327.4 for 2017) plus Notes Payable and Current Portion of Long-Term Debt ($51.8 for 2018 and $194.7 for 2017) All financial data set forth in this annual report relates solely to continuing operations unless otherwise indicated. 2018 Annual Report Dear Shareholders, As I begin my 30th year at Danaher, it is humbling to reflect on what our team has achieved over that time and exciting to think about the opportunities that still lie ahead. Financially and strategically, 2018 was an outstanding year. With the Danaher Business System (DBS) as our driving force, we strengthened our footholds in attractive, fast-growing markets and enhanced our competitive positions.
    [Show full text]
  • 2012 Annual Report 1 Table of Contents
    2012 ANNUAL REPORT 1 TABLE of CONTENTS Environmental 2 Test & Measurement 4 Dental 6 Life Sciences & Diagnostics 8 Industrial Technologies 10 Letter to the Shareholders 12 2012 Form 10-K 16 Supplemental Financial Information 141 Directors & Executive Officers 143 Shareholder Information 144 DANAHER FINANCIAL OPERATING HIGHLIGHTS (dollars in millions, except per share data and number of associates) 2012 2011 Sales* $ 18,260.4 $ 16,090.5 Operating Profit* $ 3,165.1 $ 2,617.2 Net Earnings* $ 2,299.3 $ 1,935.3 Earnings per share (diluted)* $ 3.23 $ 2.77 Operating Cash Flow* $ 3,502.1 $ 2,732.1 Capital Expenditures* $ 458.3 $ 334.5 Free Cash Flow (operating cash flow less capital expenditures)* $ 3,043.8 $ 2,397.6 Number of Associates 63,000 59,000 Total Assets $ 32,941.0 $ 29,949.5 Total Debt $ 5,343.1 $ 5,305.2 Stockholders’ Equity $ 19,083.9 $ 16,971.8 Total Capitalization (total debt plus stockholders’ equity) $ 24,427.0 $ 22,277.0 *from continuing operations Environmental We provide products that help protect our water supply and air quality by serving two primary markets: water quality and retail/commercial petroleum. Our water quality business provides instrumentation and disinfection systems to help analyze and manage the quality of ultra- pure, potable, waste, ground and ocean water in residential, commercial, industrial and natural resource applications. Our retail/commercial petroleum business is a leading worldwide provider of solutions and services focused on fuel dispensing, remote fuel management, point-of- sale systems, payment systems and environmental compliance. 3 Test & Measurement We are a global provider of electronic measurement instruments, professional test tools, thermal imaging and calibration equipment used in electrical and industrial applications.
    [Show full text]
  • Danaher 01/26
    DANAHER Danaher, a diversified technology leader, designs, manufactures, and markets innovative products and services with strong brand names and significant market positions. Driven by strong core values and a foundation provided by the Danaher Business System, Danaher’s associates are pursuing a focused strategy aimed at creating a Premier Global Enterprise. ENERGIZED BY THE DANAHER BUSINESS SYSTEM In the mid-1980s, a Danaher division faced with intensifying competition launched an improvement effort THE CHALLENGE based on the then-new principles of lean manufacturing. The initiative succeeded beyond expectations – reinforcing the division's industry leadership as well as spawning the Danaher Business System (DBS). Since this modest beginning, DBS has evolved from a collection of manufacturing improvement tools into a philosophy, set of values, and series of management processes that collectively define who we are 2003 ANNUAL REPORT and how we do what we do. Fueled by Danaher's core values, the DBS engine drives the company through a never-ending cycle of 2099 Pennsylvania Avenue NW, 12th Floor 2003 ANNUAL REPORT change and improvement: exceptional people develop outstanding plans and execute them using world- Washington, DC 20006 class tools to construct sustainable processes, resulting in superior performance. Superior performance and high expectations attract additional exceptional people, who continue the cycle. Guiding all efforts 202.828.0850 is a simple approach rooted in four customer-facing priorities: Quality, Delivery, Cost,
    [Show full text]
  • EU Top Applicants 2010-2014 Based on Assignees2014 5Yr.Tsv
    EU top applicants 2010-2014 Based on Assignees2014 5yr.tsv table_row ordering_cd 15943 309 13406 105 13407 105 13408 105 13409 105 13410 105 13411 105 13412 105 13413 105 13414 105 13415 105 13416 105 13417 105 13418 105 13419 105 13420 105 13421 105 13422 105 13423 105 13424 105 Page 1 of 1235 09/26/2021 EU top applicants 2010-2014 Based on Assignees2014 5yr.tsv st_country_cd us_or_foreign FRX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) Page 2 of 1235 09/26/2021 EU top applicants 2010-2014 Based on Assignees2014 5yr.tsv state_country_of_origin assignee_name FRANCE IMERJ, LTD. AUSTRIA INFINEON TECHNOLOGIES AG AUSTRIA ~INDIVIDUALLY OWNED PATENT AUSTRIA AMS AG AUSTRIA NXP B.V. AUSTRIA JULIUS BLUM GMBH AUSTRIA BAXTER INTERNATIONAL INC. AUSTRIA EPCOS AG AUSTRIA INFINEON TECHNOLOGIES AUSTRIA AG AUSTRIA MED-EL ELEKTROMEDIZINISCHE GERAETE GMBH AUSTRIA SIEMENS AKTIENGESELLSCHAFT AUSTRIA AVL LIST GMBH AUSTRIA MAGNA POWERTRAIN AG & CO KG AUSTRIA HILTI AKTIENGESELLSCHAFT AUSTRIA BOEHRINGER INGELHEIM INTERNATIONAL GMBH AUSTRIA FRONIUS INTERNATIONAL GMBH AUSTRIA SIEMENS VAI METALS TECHNOLOGIES GMBH AUSTRIA CONTINENTAL AUTOMOTIVE GMBH AUSTRIA INTEL MOBILE COMMUNICATIONS GMBH AUSTRIA MAGNA STEYR FAHRZEUGTECHNIK AG & CO. KG Page 3 of 1235 09/26/2021 EU top applicants 2010-2014 Based on Assignees2014 5yr.tsv CY_2010 CY_2011
    [Show full text]
  • INVESTOR & ANALYST MEETING December 16, 2015
    INVESTOR & ANALYST MEETING December 16, 2015 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future, are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, deterioration of or instability in the economy, the markets we serve and the financial markets, the impact of our restructuring activities on our ability to grow, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new and enhanced products and services and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our ability to successfully identify, consummate and integrate appropriate acquisitions and successfully complete divestitures and other dispositions, our ability to integrate the recently acquired Pall Corporation and achieve the anticipated benefits of that transaction, our ability to successfully consummate the separation of Danaher into two public companies and realize the anticipated benefits of that transaction, contingent liabilities relating to
    [Show full text]
  • Company Vendor ID (Decimal Format) (AVL) Ditest Fahrzeugdiagnose Gmbh 4621 @Pos.Com 3765 0XF8 Limited 10737 1MORE INC
    Vendor ID Company (Decimal Format) (AVL) DiTEST Fahrzeugdiagnose GmbH 4621 @pos.com 3765 0XF8 Limited 10737 1MORE INC. 12048 360fly, Inc. 11161 3C TEK CORP. 9397 3D Imaging & Simulations Corp. (3DISC) 11190 3D Systems Corporation 10632 3DRUDDER 11770 3eYamaichi Electronics Co., Ltd. 8709 3M Cogent, Inc. 7717 3M Scott 8463 3T B.V. 11721 4iiii Innovations Inc. 10009 4Links Limited 10728 4MOD Technology 10244 64seconds, Inc. 12215 77 Elektronika Kft. 11175 89 North, Inc. 12070 Shenzhen 8Bitdo Tech Co., Ltd. 11720 90meter Solutions, Inc. 12086 A‐FOUR TECH CO., LTD. 2522 A‐One Co., Ltd. 10116 A‐Tec Subsystem, Inc. 2164 A‐VEKT K.K. 11459 A. Eberle GmbH & Co. KG 6910 a.tron3d GmbH 9965 A&T Corporation 11849 Aaronia AG 12146 abatec group AG 10371 ABB India Limited 11250 ABILITY ENTERPRISE CO., LTD. 5145 Abionic SA 12412 AbleNet Inc. 8262 Ableton AG 10626 ABOV Semiconductor Co., Ltd. 6697 Absolute USA 10972 AcBel Polytech Inc. 12335 Access Network Technology Limited 10568 ACCUCOMM, INC. 10219 Accumetrics Associates, Inc. 10392 Accusys, Inc. 5055 Ace Karaoke Corp. 8799 ACELLA 8758 Acer, Inc. 1282 Aces Electronics Co., Ltd. 7347 Aclima Inc. 10273 ACON, Advanced‐Connectek, Inc. 1314 Acoustic Arc Technology Holding Limited 12353 ACR Braendli & Voegeli AG 11152 Acromag Inc. 9855 Acroname Inc. 9471 Action Industries (M) SDN BHD 11715 Action Star Technology Co., Ltd. 2101 Actions Microelectronics Co., Ltd. 7649 Actions Semiconductor Co., Ltd. 4310 Active Mind Technology 10505 Qorvo, Inc 11744 Activision 5168 Acute Technology Inc. 10876 Adam Tech 5437 Adapt‐IP Company 10990 Adaptertek Technology Co., Ltd. 11329 ADATA Technology Co., Ltd.
    [Show full text]
  • Danaher Corporation
    9-708-445 REV: APRIL 15, 2011 BHARAT ANAND DAVID J. COLLIS S O P H I E H O OD Danaher Corporation In early April 2010, Danaher Corporation’s Chief Executive Officer Larry Culp and his senior executive team were getting ready for another round of performance reviews of the firm’s diverse operating businesses. As usual at Danaher, this process was likely to involve not only conference room presentations but visits to the factory floor and conversations with customers. Culp had joined Washington D.C.-based Danaher after graduating from Harvard Business School in 1990, and was appointed CEO in 2001 at the age of 38. He had taken over a company that had generated compound annual stock returns of over 25% since its founding in 1985. Under Culp’s leadership so far, Danaher’s performance continued unabated. Between 2001 and 2006, Danaher’s revenues and net income more than doubled, the firm consummated over 50 acquisitions, and its stock price continued to outperform its peers by impressive margins1 (see Exhibit 1). And, while the “great recession” of 2008-09 impacted its businesses like any other industrial conglomerate, the company emerged relatively unscathed. Indeed, Culp was about to announce higher than expected earnings for yet another quarter. Culp was wary of the term “conglomerate,” instead referring to Danaher as a family of strategic growth platforms. Management defined a strategic growth platform as “a multi-billion-dollar market in which Danaher can generate $1 billion or more in revenue while being No. 1 or No. 2 in the market.”2 In 2010, Danaher’s portfolio comprised five such platforms, representing over 80% of its total revenue.
    [Show full text]
  • 2016-17 Corporate Social Responsibility Report
    2016-17 Corporate Social Responsibility Report 04 06 10 14 18 20 GUIDING IMPROVING ASSOCIATE AND ENVIRONMENT, INTEGRITY AND CORPORATE PRINCIPLES QUALITY OF COMMUNITY HEALTH AND COMPLIANCE GOVERNANCE LIFE THROUGH ENGAGEMENT SAFETY INNOVATION STEWARDSHIP From Our CEO This has been a year of transformation for Danaher, as we prepared for and navigated the spin-off of Fortive Corporation into an independent public company, welcomed Pall Corporation and other new businesses into the Danaher family, and began an exciting next chapter with the articulation of Our Shared Purpose: Helping Realize Life’s Potential. Our Shared Purpose inspires us to focus all that we do for the benefit of our shareholders, the development of our associates, and the good of our customers, our communities and our planet. This 2016-2017 Corporate Social Responsibility (CSR) Report, the follow-up to our 2014-2015 report, is an ideal opportunity to showcase it in action. As you know, Danaher’s tradition of CSR extends far beyond the publication of our first official report two years ago. For more than three decades, it has been woven into the fabric of our Core Values, the Danaher Business System (DBS) and our team-oriented culture, which set a high bar for professional growth, innovation and continuous improvement in the service of our stakeholders. On a daily basis, our businesses improve health and safety around the world. Our products and services assist in life-saving research and diagnostics, protect consumer packaging and contribute to environmental stewardship in substan- tive ways. In these pages, you’ll see how Laetus helps protect consumers around the world by making it easy and efficient to comply with pharmaceutical tracing regulations.
    [Show full text]